Sputnik V. Photo: Reuters
Sputnik V. Photo: Reuters
Leading hospital chain Manipal Hospitals on Sunday said it has collaborated with Dr Reddy's Laboratories to add the Sputnik V COVID-19 vaccine in its existing vaccine portfolio that consists of Covishield and Covaxin.
The roll-out of the Sputnik V vaccine by Manipal Hospitals in Bengaluru is part of the limited pilot soft launch initiated by Dr Reddy's in Hyderabad last month, Manipal Hospitals said in a statement.
"Manipal Hospitals has worked closely with Dr Reddy's to create the state-of-the-art infrastructure to maintain Sputnik V vaccine," Manipal Health Enterprises Chief Operating Officer Karthik Rajagopal said.
He added that the hospital chain has successfully conducted vaccination drives with Covishield and Covaxin across the country till date and will continue the efforts along with the new addition of Sputnik V.
Manipal Hospitals expects the vaccine to be available for the public soon in the latter half of the month, Rajagopal said.
"We are pleased to collaborate with Manipal Hospital in Bengaluru as we scale up our soft pilot launch of the Sputnik V vaccine in India and extend it to more cities ahead of the commercial launch later in June.
"In the upcoming months, we hope to inoculate as many Indians as possible," Dr Reddy's Branded Markets (India and Emerging Markets) CEO M V Ramana said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.